GSA Capital Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$40K Buy
+15,088
New +$52.3K ﹤0.01% 1787
2026
Q1
– Sell
-36,836
Closed -$129K – 2087
2025
Q4
$129K Sell
36,836
-187,440
-84% -$642K 0.01% 1503
2025
Q3
$731K Buy
224,276
+187,037
+502% +$589K 0.06% 596
2025
Q2
$91K Buy
37,239
+12,607
+51% +$63.9K 0.01% 1623
2025
Q1
$164K Buy
+24,632
New +$243K 0.01% 1439
2022
Q4
– Sell
-54,582
Closed -$871K – 1815
2022
Q3
$871K Buy
54,582
+33,293
+156% +$520K 0.12% 220
2022
Q2
$293K Buy
+21,289
New +$254K 0.04% 840
2022
Q1
– Sell
-35,704
Closed -$779K – 1756
2021
Q4
$779K Buy
+35,704
New +$974K 0.1% 328
2021
Q1
– Sell
-6,699
Closed -$367K – 1416
2020
Q4
$367K Sell
6,699
-13,767
-67% -$502K 0.06% 630
2020
Q3
$468K Buy
+20,466
New +$504K 0.08% 431
2018
Q1
– Sell
-3,325
Closed -$35K – 1782
2017
Q4
$35K Sell
3,325
-88,500
-96% -$877K ﹤0.01% 1511
2017
Q3
$654K Buy
91,825
+52,750
+135% +$241K 0.04% 793
2017
Q2
$297K Buy
39,075
+1,625
+4% +$12.1K 0.02% 1282
2017
Q1
$300K Buy
+37,450
New +$252K 0.02% 1384

Other funds holding RCKT

GSA Capital Partners's RCKT Position: Q3 2026 in Review

GSA Capital Partners opened a new position in Rocket Pharmaceuticals (RCKT) in Q3 2026: 15,088 shares worth $40K. The stake represents ﹤0.01% of the portfolio and ranks #1787 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in RCKT as recently as Q4 2025.

GSA Capital Partners first reported a position in RCKT in Q1 2017 and has held it in 14 quarters since. The position peaked at $871K in Q3 2022. 175 funds tracked by Wall St. Rank hold RCKT as of Q3 2026.

  • GSA Capital Partners held 15,088 shares of Rocket Pharmaceuticals worth $40K as of Q3 2026.
  • Rocket Pharmaceuticals was a new GSA Capital Partners position in Q3 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of GSA Capital Partners's portfolio in Q3 2026, its #1787 holding.
  • GSA Capital Partners first reported a position in Rocket Pharmaceuticals in Q1 2017 and has held it in 14 quarters since.
  • GSA Capital Partners's Rocket Pharmaceuticals position peaked at $871K in Q3 2022.
  • 175 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.